

## REMARKS

Claims 57 – 68 are pending, with claim 68 having been withdrawn from consideration pursuant to an election of species. Claims 57, 59 and 60 are amended herein. No claims are cancelled or added. Accordingly, after entry of the amendments, claims 57 – 69 are pending, with claim 68 standing withdrawn.

All prior rejections have been withdrawn in favor of new rejections of the pending claims under 35 U.S.C. § 103.

### Amendments to the claims

Claims 57, 59 and 60 have been amended to recite broader safinamide dosage ranges. Support for the amendments can be found, *e.g.*, at page 19, lines 4 – 19. No new matter has been added.

### Rejections Under 35 U.S.C. § 103(a)

Claims 57 – 64 and 67 have been rejected under 35 U.S.C. § 103 as having been obvious over Chiesi, U.S. Pat. No. 5,017,607 (“Chiesi”) and Dostert *et al.*, U.S. Pat. No. 5,236,957 (“Dostert”). Claims 65 and 66 have been rejected under 35 U.S.C. § 103 as having been obvious over Chiesi and Dostert, further in view of Chenard, U.S. Pat. No. 6,258,827 (“Chenard”).

Chiesi discloses the use of levodopa methyl ester (“LDME”), a levodopa prodrug, in the treatment of idiopathic Parkinson’s disease, optionally in combination with selective MAO-B inhibitors, such as deprenyl. Chiesi does not disclose the use of safinamide. Dostert discloses the treatment of idiopathic Parkinson’s disease with safinamide<sup>1</sup>, which is identified as a “potent inhibitor of monoamine oxidase (MAO), but “does not teach the coadministration of L-Dopa which is administered in an amount that alone has therapeutic effect,” Office action, page 5. Citing to *In re Kerkhoven*, the Examiner argues that it would have been *prima facie* obvious “to

---

<sup>1</sup> A divisional, U.S. Pat. No. 5,502,079 (of record), *claims* methods of treating Parkinson’s disease with safinamide.

combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose,” that “it would have been obvious to ... have combined L-dopa (with or without [a] decarboxylase inhibitor) with safinamide in the treatment of Parkinson’s disease.” Office Action, page 6.

Applicants traverse.

Chiesi explicitly teaches that the addition of an MAO-B inhibitor to therapy with levodopa methyl ester “allow[s] a remarkable reduction in the dose of LDME necessary to control the disease, consequently decreasing side effects...” Chiesi, col. 3, lines 9 – 16. The reference is thus fairly read as teaching away from combination therapies in which L-dopa (or prodrug thereof) is administered “in an amount that alone has therapeutic effect,” as required by applicants’ claims.<sup>2</sup>

That MAO-B inhibitors permit remarkable reductions in L-dopa dosage is not a remarkable observation, nor original to Chiesi: inhibition of central catabolic pathways has long been known to permit effective concentrations of L-dopa (and thus, of dopamine) to be achieved in brain using lower administered dosages of L-dopa; indeed, a primary purpose of adjunctive administration of MAO-B inhibitors is to permit just such dosage reduction, with concomitant reduction of side effects.

Safinamide, however, is not simply a selective MAO-B inhibitor – it also blocks voltage-sensitive sodium channels, inhibits glutamate release, and blocks dopamine uptake, Caccia *et al.*, “Safinamide: from molecular targets to a new anti-Parkinson drug,” *Neurology* 67 (suppl. 2):S18-S23 (2006)<sup>3</sup> – and has therapeutic effects in Parkinson’s disease beyond those accounted for by MAO-B inhibition, Stocchi *et al.*, “Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition,” *Neurology* 67 (suppl

---

<sup>2</sup> Proceeding contrary to accepted wisdom in the art is of course evidence of *nonobviousness*. *In re Hedges*, 783 F.2d 1038, 228 USPQ 685 (Fed. Cir. 1986).

<sup>3</sup> Attached hereto as Exhibit A.

2):S24-S29 (2006) (“Stocchi”).<sup>4</sup> As a consequence, safinamide can be added to a stable and therapeutically effective L-dopa regimen, providing additional symptomatic benefit. This would neither have been predicted nor reasonably expected from the prior art.

Stocchi reports the results of an open-label study of safinamide as an add-on to levodopa.

In association with levodopa, ... [100, 150, 200 mg po QD] doses of safinamide induced a significant decrease in motor fluctuations (UPDRS part IV, 2.1 points;  $P < 0.001$ ).... Because MAO-B was fully inhibited (95%) at all doses tested, we suggest that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine reuptake.

Stocchi, Abstract. These results were achieved against a background of “pre-existing optimal [levodopa] treatment regimen....” Stocchi, S29, col. 1 (emphasis added).

Reduction in “off” time in the setting of optimal levodopa treatment is an important therapeutic benefit: prior to addition of safinamide, the study patients “were suffering from motor fluctuations while receiving a stable dosage of L-dopa (plus a decarboxylase inhibitor),” Stocchi, S25, col. 1.

In addition to the statistically significant reduction in motor fluctuations and dyskinesias, which are side effects of levodopa therapy, a beneficial trend was observed with respect to scores on UPDRS Part III, which measures the primary motoric dysfunction of Parkinson’s disease.<sup>5</sup> Stocchi, S27, col. 1.

The beneficial trend in UPDRS III scores first reported in Stocchi has now been confirmed, and demonstrated to reach statistical significance, in a 24 week, multi-center, randomized, double-blind, placebo-controlled study. Meshram *et al.*, “Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late


---

<sup>4</sup> Attached hereto as Exhibit B (already of record). This post-filing date publication includes among its authors two of the instant inventors and reports results from clinical trials sponsored by the owner of the instant application, Newron Pharmaceuticals SpA.

<sup>5</sup> UPDRS Part III measures severity of motor signs, the fundamental motor symptoms of the disease itself, including tremor, facial and generalized bradykinesia, and further includes performance measures on several tasks are used to rate disease severity.

Parkinson's disease," Poster 359, Movement Disorder Society 14<sup>th</sup> International Congress, Buenos Aires, Argentina, 13-17 June 2010 ("Meshram").<sup>6</sup>

As reported by Meshram, both doses of safinamide (50 mg/day and 100 mg/day), when added to a stable dose of levodopa – a dose that had been clinically optimized prior to study entry – “were associated with significant improvements in UPDRS Part III (motor examination) scores versus placebo (Figure 3)”:



No other drug has been demonstrated to provide motor benefits additional to those seen with optimal doses of levodopa, the gold standard for Parkinson's disease treatment.

These results could not have been predicted from safinamide's known MAO-B inhibitory activity. As noted by Stocchi, safinamide efficacy increases at doses above that required for complete MAO-B inhibition, “results ... [that] support the hypothesis that MAO-B inhibition is a minor contributor to the symptomatic effect of safinamide in PD.” Stocchi, p. 28, col. 2.

<sup>6</sup> Attached hereto as Exhibit C. As noted on the Poster, “This study was funded by Newron and Merck Serono SA-Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.” Newron is the owner of the instant application, and Merck Serono is a licensee.

And although Stocchi speculate that, “glutamate release inhibition should occur at the doses used,” the authors continue that “its exact role is still under investigation.” Stocchi, S28 col. 2 – S29, col. 1. Furthermore, even if safinamide’s motoric benefits as an add-on to levodopa were ultimately to be attributed to its glutamate release inhibitory properties, the reported results would not have been expected: “[a]ll the clinically available putative anti-glutamate drugs have thus far failed to demonstrate motor improvement in clinical trials,” Stocchi, S 29, col. 1. *See, e.g., Rascol et al.*, “A 2-year, multicenter, placebo-controlled, double-blind, parallel group study of the effect of riluzole on Parkinson’s disease progression,” *Movement Disorders*, 17 (Suppl. 5), S29 (2002).<sup>7</sup>

Furthermore, the same double-blind study reported in Meshram demonstrates that addition of safinamide to clinically optimized stable doses of levodopa also improves symptoms of depression, a non-motor symptom seen often in mid- to late-stage Parkinson’s disease, with improvements reaching statistical significance at 100 mg/day safinamide. *Borghain et al.*, “Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson’s disease,” Poster 324, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010 (“Borghain”) (attached hereto as Exhibit E). Nothing in Dostert or Chiesi would have predicted these results.

Neither Dostert nor Chiesi would properly have motivated methods of treating Parkinson’s disease with safinamide as an add-on to dosages of L-dopa that alone have therapeutic effect – thus vitiating the purported *prima case* of obviousness. In addition, the results of so doing were unexpected, and unexpectedly superior to results previously achieved, providing clear and compelling secondary evidence of nonobviousness. The claimed invention is nonobvious and the rejections should be withdrawn.<sup>8</sup>

---

<sup>7</sup> Attached hereto as Exhibit D.

<sup>8</sup> Chenard is added as a tertiary reference in rejection of claims 65 and 66 for its teaching of the adjunctive use of COMT inhibitors, such as tolcapone or entacapone. With failure of the primary and secondary reference to motivate the use of safinamide as an “add-on” to doses of levodopa that “alone

## CONCLUSION

Claims 57 – 68 are pending, with claim 68 currently withdrawn from prosecution

The sole rejections remaining in this application, rejection of claims 57 – 67 under 35 U.S.C. § 103, have been traversed. The rejections are in error, and should be withdrawn.

### Rejoinder

Claim 57 is generic to the species of “Parkinson’s disease agent” previously elected for prosecution on the merits, L-Dopa. Claim 57 recites:

A method of treating idiopathic Parkinson’s disease, comprising:  
orally administering safinamide, or a pharmaceutically acceptable salt thereof, on a daily dosage schedule of about 0.5 mg/kg/day to about 2 mg/kg/day to a patient with idiopathic Parkinson’s disease; and  
concurrently administering to the patient at least one Parkinson’s disease agent, wherein the at least one Parkinson’s disease agent is selected from the group consisting of L-Dopa and Dopamine agonists, and wherein the at least one Parkinson’s disease agent is administered in an amount that alone has therapeutic effect.

No rejections having been predicated on the combination of safinamide with a dopamine agonist, generic claim 57 is allowable. Pursuant to 37 C.F.R. §§ 1.141 and 1.146, rejoinder and allowance of claim 68, drawn to the patentably distinct species of concurrent therapy with safinamide and Dopamine agonists, is appropriate.

### Interview request

If the Examiner finds that any matters remain outstanding that preclude allowance, the Examiner is requested to contact applicants’ attorney, Daniel M. Becker, at (650) 813-4874, to schedule a personal interview.

---


have therapeutic effect,” the tertiary reference cannot save the *prima facie* case, nor rebut the compelling secondary indicia of nonobviousness.

Fees

No fees are believed to be due in connection with this response. However, the Director is authorized to charge any additional fees that may be required, or credit any overpayment, to Dechert LLP Deposit Account No. 50-2778 (**Order No.** 373987-011 US (102895)).

Respectfully submitted,

Date: 15 JUNE 2010

  
Daniel M. Becker  
Reg. No. 38,376

**DECHERT LLP**  
**Customer No. 37509**  
Tel: 650.813.4800  
Fax: 650.813.4848

- Exhibit A: Caccia *et al.*, "Safinamide: from molecular targets to a new anti-Parkinson drug," *Neurology* 67 (suppl. 2):S18-S23 (2006)
- Exhibit B: Stocchi *et al.*, "Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition," *Neurology* 67 (suppl 2):S24-S29 (2006) (already of record)
- Exhibit C: Meshram *et al.*, "Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late Parkinson's disease," Poster 359, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010.
- Exhibit D: Rascol, *et al.*, "A 2-year, multicenter, placebo-controlled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression," *Movement Disorders*, 17 (Suppl. 5), S29 (2002)
- Exhibit E: Borgohain *et al.*, "Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease," Poster 324, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010 ("Borgohain") (attached hereto as Exhibit E).

# NEUROLOGY

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

CARLO CATTANEO Change Password | View/Change User Information | CiteTrack Personal Alerts | Subscription HELP | Sign C

NEUROLOGY 2006;67:S18-S23

© 2006 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

## Safinamide

### From molecular targets to a new anti-Parkinson drug

C. Caccia, PhD, R. Maj, PhD, M. Calabresi, S. Maestroni, PhD, L. Faravelli, PhD, L. Curatolo, PhD, P. Salvati, PhD and R. G. Fariello, MD

From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.).

Address correspondence and reprint requests to Dr. Carla Caccia, Newron Pharmaceuticals Spa, Via Ludovico Ariosto 21, 20091 Bresso (MI), Italy; e-mail: carla.caccia@newron.com

## Abstract.

Ideal treatment in Parkinson's disease (PD) aims at relieving symptoms and slowing disease progression. Of all remedies, levodopa remains the most effective for symptomatic relief, but the medical need for neuroprotectant drugs is still unfulfilled.

Safinamide, currently in phase III clinical trials for the treatment of PD, is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent  $\text{Na}^+$  and  $\text{Ca}^{2+}$  channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model. Safinamide potentiates levodopa-mediated increase of DA levels in DA-depleted mice and reverses the waning motor response after prolonged levodopa treatment in 6-OHDA-lesioned rats. Safinamide has excellent bioavailability, linear kinetics, and is suitable for once-a-day administration. Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential.

QUICK SEARCH: {advanced}

Author: Keyword(s):

Go

Year:

Vol:

Page:

### This Article

- ▶ Abstract FREE
- ▶ Figures Only
- ▶ Correspondence: Submit a response
- ▶ Alert me when this article is cited
- ▶ Alert me when Correspondence are posted
- ▶ Alert me if a correction is posted
- ▶ Citation Map

### Services

- ▶ Email this article to a friend
- ▶ Similar articles in this journal
- ▶ Similar articles in PubMed
- ▶ Alert me to new issues of the journal
- ▶ Download to citation manager
- ▶ Cited by other online articles

### Google Scholar

- ▶ Articles by Caccia, C.
- ▶ Articles by Fariello, R. G.

### PubMed

- ▶ PubMed Citation
- ▶ Articles by Caccia, C.
- ▶ Articles by Fariello, R. G.

- ▲ Top.
- ▼ Abstract.
- ▼ Pharmacodynamic properties.
- ▼ Conclusions.
- ▼ Acknowledgment
- ▼ References



Parkinson's disease (PD) is a progressive neurodegenerative syndrome that begins insidiously and gradually worsens in severity. The neurodegenerative processes result from the loss of dopaminergic (DA) neurons that project into the striatum from the substantia nigra pars compacta, leading to the motor symptoms of the disease.<sup>1</sup> The reasons for this neuron loss remain unknown, and although specific genes, including  $\alpha$ -synuclein and parkin, have been identified as causal in several patients,<sup>2,3</sup> it is likely that the majority of PD cases are a result of both genetic and environmental factors.<sup>4</sup> The early motor symptoms and signs of PD, i.e., resting tremor, bradykinesia, and rigidity, are usually treated with levodopa and DA agonists. As PD progresses over time, symptoms that do not respond to levodopa develop, such as fluctuations in motor performance, the freezing phenomenon, and loss of postural reflexes. These are often referred to as non-DA-related features of PD. Moreover, bradykinesia that responded to levodopa in the early stage of PD increases as the disease worsens and no longer fully responds to levodopa.<sup>5</sup>

Significant advances have been made in understanding the molecular and cellular factors involved in the pathogenesis of PD, but satisfactory approaches to relieve late symptoms and to slow the progression of the disease (i.e., protecting DAergic neurons from premature death) have not been developed. Although promising results have been obtained experimentally with several classes of drugs,<sup>6,7</sup> none of the current treatments has been clinically proved to arrest or even delay neuron loss in PD.


Current symptomatic treatment relies on such agents as levodopa, DA agonists, MAO-B inhibitors, and catechol-*O*-methyltransferase (COMT) inhibitors that compensate for the deficit in the nigrostriatal DAergic input pathways, but it is now accepted that several other events contribute to disease progression. These include oxidative stress with free radical production,<sup>8</sup> neuroinflammation,<sup>9</sup> alterations in the ubiquitin-proteasome system leading to apoptosis,<sup>10</sup> mitochondrial dysfunctions,<sup>11</sup> and excitotoxicity mediated by excessive glutamate release.<sup>12</sup> Novel drugs combining multiple biochemical actions may have both symptomatic and neuroprotective effects. In this regard, safinamide is a new molecule with multiple mechanisms of action and experimental evidence supporting clinical trials to confirm its symptomatic and neuroprotecting potential.

## ► Pharmacodynamic properties.

Safinamide, (S)-(+)-2-[4-(3-fluorobenzoyloxy-benzylamino) propion-amide] (figure 1) is a small molecule, chemically and metabolically stable, and water soluble, combining low CNS toxicity and multiple mechanisms of action. These include specific and potent modulation of DA metabolism, blockade of  $\text{Na}^+/\text{Ca}^{2+}$  channels, and inhibition of glutamate release. The unique combination of these properties offers the potential of combining symptomatic relief (by DA modulation) and neuroprotection (by  $\text{Na}^+/\text{Ca}^{2+}$  and glutamate release blockade) in PD.

- ▲ Top,
- ▲ Abstract,
- \* Pharmacodynamic properties,
- ▼ Conclusions,
- ▼ Acknowledgment
- ▼ References

Figure 1. Chemical structure of safinamide.




**View larger version (11K):**

[\[in this window\]](#)

[\[in a new window\]](#)

**Effects on monoamine metabolism.** MAO is a key enzyme in the catabolism of DA, leading to the formation of potentially toxic byproducts within nigral neurons and in the adjacent glia. Along with this oxidation step, some free radicals and other reactive oxygen species are generated, resulting in oxidative stress and eventually in neuron death. In monkey and human brain, DA is preferentially (more than 80%) metabolized by MAO-B. With MAO-B inhibited, the oxidative deamination of both endogenous and exogenous levodopa-derived DA decreases and DA levels increase with restored dopaminergic function.<sup>1,3</sup> In addition, MAO-B inhibition may prevent activation of toxins and free radicals formed by oxidative steps, possibly reducing the progression of neurodegenerative processes.<sup>1,4,15</sup> Safinamide is a highly selective MAO-B inhibitor in rat brain mitochondria, with an  $IC_{50}$  of 98 nM. It is about 5000-fold more potent in inhibiting MAO-B versus MAO-A (figure 2A). With the same potency, safinamide inhibits MAO-B in human brain and is even more potent in inhibiting MAO-B in human platelets, with an  $IC_{50}$  of 9 nM (figure 2B). Unlike clinically used MAO-B inhibitors, enzyme inhibition by safinamide is reversible. It is not dependent on preincubation time between the enzyme and the inhibitor, as shown by no difference between  $IC_{50}$  values with or without preincubation (figure 2C). This means that enzyme inhibition is immediately reached after enzyme/inhibitor complex formation without need for a covalent binding, as is typical for irreversible inhibition.



**View larger version (27K):**

[\[in this window\]](#)

[\[in a new window\]](#)

**Figure 2.** *In vitro and in vivo effects of safinamide on MAO enzyme activity: (A) In vitro effects on MAO-A and MAO-B in rat brain mitochondria. (B) In vitro effects on MAO-B in human platelets and brain. (C) Time-dependent effect on MAO-B in human platelets. (D) In vivo effects on MAO-A and MAO-B after oral treatment; comparison with rasagiline.*

In *ex vivo* experiments after oral treatment, safinamide dose-dependently inhibits mouse brain MAO-B, leaving MAO-A virtually unaffected. MAO-B activity recovers quickly, starting from 8 hours, suggesting that *in vivo* safinamide is a specific and short-acting MAO-B inhibitor, as expected

of a reversible inhibitor. Conversely, rasagiline's long-lasting inhibition of MAO-B does not show recovery up to 24 hours, as is typical of irreversible inhibitors (figure 2D).

The MAO-B inhibitory effect of safinamide was also found in plasma-rich platelets of healthy volunteers after a single series of ascending oral doses (25 to 2500 µg/kg). Complete inhibition (90%) was seen at 600 µg/kg with an ED<sub>50</sub> of 87 µg/kg (figure 3). After chronic administration in cynomolgus monkeys (13 weeks, 10 and 20 mg/kg orally), safinamide at 24 hours after the last treatment significantly increased brain DA levels (27% and 48%, respectively), with a concomitant decrease of the metabolite dihydroxyphenylacetic acid (-19% and -41%, respectively) in the putamen. In parallel, MAO-B was found significantly inhibited.




Figure 3. Effect of single ascending oral dose of safinamide on platelet MAO-B activity in healthy volunteers.


View larger version (20K):  
[\[in this window\]](#)  
[\[in a new window\]](#)

After 39 weeks of treatment, the magnitude of the DA increment was similar to that found after 13 weeks, indicating that safinamide does not induce tolerance even after chronic treatment. In the same safinamide-treated animals, hippocampal levels of serotonin and its metabolite and cortical levels of norepinephrine (both produced by MAO-A-mediated catabolism) were not affected.

**Biochemical and pharmacologic effects in animal models.** Safinamide was tested in different animal models of PD, such as add-ons to levodopa in DA-depleted animals, the "wearing-off" model in denervated levodopa-treated rats,<sup>16</sup> and the *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model.

**Add-on to levodopa in DA-depleted mice.** Physiologically, DA catabolism in rodent brain is primarily MAO-A-mediated. In fact, safinamide up to 80 mg/kg orally had no effect on striatal DA metabolism in rats. As shown in figure 4, in DA-depleted C57BL mice (15 days after MPTP treatment), safinamide (20 mg/kg IP) significantly increases DA levels (60%) when coadministered with levodopa (100 mg/kg IP + benserazide 12.5 mg/kg IP). Safinamide does not inhibit COMT activity in vitro or in vivo.

Figure 4. Effect of safinamide on brain DA levels in levodopa-treated C57BL mice (15 days after MPTP). \*\**P* < 0.01.



View larger version (31K):

[\[in this window\]](#)

[\[in a new window\]](#)

These findings agree with the hypothesis that deamination of DA by glial MAO-B becomes more prominent when catabolism by MAO-A in the dopaminergic nerve terminals has been compromised, such as in the MPTP model, and strongly support the use of safinamide as add-on therapy with levodopa in PD patients.

**"Wearing-off" model in denervated levodopa-treated rats.** In 6-hydroxydopamine (6-OHDA)-lesioned rats, turning evoked by injection of the same dose of levodopa decreases after chronic treatment (25 mg/kg IP for 28 days). In particular, the duration of rotations becomes significantly shorter during the course of levodopa treatment, mimicking the "wearing-off" phenomenon observed in PD patients. At time of appearance of this motor complication there is a consistent imbalance between dopaminergic and glutamatergic systems in favor of an increased excitatory input.<sup>16</sup> Using this model, we showed that on day 29 the decreased response to levodopa is reversed by single co-administration of safinamide (20 mg/kg IP). This effect is more pronounced than that obtained with the glutamate antagonist MK-801 (figure 5).




Figure 5. Effect of safinamide on the rotational response to chronic levodopa in 6-OHDA-lesioned rats. <sup>a</sup> $P < 0.05$  vs levodopa on day 1; <sup>\*</sup> $P < 0.05$  vs levodopa on day 28.

View larger version (17K):

[\[in this window\]](#)

[\[in a new window\]](#)

The potentiation of the levodopa response supports the hypothesis of additional neuroprotective mechanisms beyond restoration of DA levels in the antiparkinson activity of safinamide. Inhibition of glutamate release is likely to be one of them.

**MPTP model in mice (prophylactic schedule).** Fifteen days after injection, the meperidine derivative MPTP causes severe DA depletion and cell death of nigrostriatal dopaminergic neurons. By MAO-B, MPTP is converted to its toxic metabolite MPP<sup>+</sup>. Blockade of this reaction prevents MPTP neurotoxicity. Given before MPTP, safinamide at all doses tested inhibits striatal DA depletion and

preserves nigral cell death by blocking MAO-B, as detected immunohistochemically by counting tyrosine hydroxylase-positive neurons (data not shown).

*Effect on sodium and calcium channels.* Safinamide has high affinity for the  $\text{Na}^+$  channel-binding site II in rat cortical membranes, with an  $\text{IC}_{50}$  of 8  $\mu\text{M}$ . The binding site II is a specific binding site internal to the channel pore where drugs with blocking activity bind. Safinamide has no affinity for more than 80 different types of receptors, such as dopamine, glutamate, adenosine, serotonin, muscarinic, and nicotinic, as well as GABA.

Binding to the  $\text{Na}^+$  channel is functionally active. In fact, safinamide inhibits the fast  $\text{Na}^+$  currents in a concentration- and state-dependent manner (different potency at different states of the channel) in rat cortical neurons, as assessed by patch clamp. At depolarized membrane potentials, when a large number of channels are in the inactivated state mimicking neuronal pathologic conditions, safinamide is three times more potent ( $\text{IC}_{50}$  33  $\mu\text{M}$ ) than at resting potential ( $\text{IC}_{50}$  96  $\mu\text{M}$ ), suggesting a preferential interaction with the inactivation state of the channel. Therefore, in the presence of safinamide a much higher proportion of  $\text{Na}^+$  channels is kept in the inactivated state and prevented from activating. The state-dependent blockade is also confirmed using a cell line transfected with the sodium subtype Nav1.3, the most abundant sodium channel subtype in the brain.

In addition, the blockade of  $\text{Na}^+$  currents by safinamide is use-dependent, meaning an enhancement of the blockade during high-frequency stimulation when there is a large accumulation of channels in the inactivated state. Functionally, the use-dependent blockade results in depression of neuronal activity at high-frequency firing and ineffectiveness at a normal firing rate, suggesting that safinamide will selectively depress abnormal activity, leaving unaffected the physiologic activity and thus avoiding CNS depressant effects.

Safinamide inhibits the action potential firing in cortical neurons, slowing recovery from the inactivation state and thus reducing channel availability for subsequent  $\text{Na}^+$  spikes.

Safinamide blocks N-Type  $\text{Ca}^{2+}$  currents in rat cortical neurons ( $\text{IC}_{50}$  23  $\mu\text{M}$ ), suggesting that it might participate in the inhibition of neurotransmitter presynaptic release (e.g., excitatory amino acids), mostly influenced by the activation of N-type  $\text{Ca}^{2+}$  channels. In vivo, peripheral L-type  $\text{Ca}^{2+}$  channels are not affected by safinamide, as demonstrated by no effects per se on blood pressure and heart rate or on the pressor response to norepinephrine in the pithed rat up to 50 mg/kg IP.

*Effect on glutamate.* Safinamide inhibits glutamate release induced by depolarizing conditions in rat hippocampal synaptosomes ( $\text{IC}_{50}$  9  $\mu\text{M}$ ). At high  $\text{K}^+$  concentrations, the release of the neurotransmitter is  $\text{Ca}^{2+}$ -mediated. Therefore, safinamide, by blocking N-Type  $\text{Ca}^{2+}$  mobilization, inhibits glutamate release, one of the most relevant excitotoxic inputs leading to neuron death.

*Pharmacologic effects in neuroprotection/neurorescuing models.* Taking into account the  $\text{Na}^+/\text{Ca}^{2+}$  channel and glutamate release inhibitory properties, safinamide was investigated in several in vitro and in vivo models of neuroprotection not attributable to MAO-B-related mechanisms.

**In vitro veratridine-induced neuron cell death.** The prolonged opening of veratridine-sensitive  $\text{Na}^+$

channels in neuron cultures results in  $\text{Ca}^{2+}$ -dependent cell degeneration. The damage can be prevented by  $\text{Ca}^{2+}$  and/or  $\text{Na}^{+}$  blockers. In rat primary cortical neurons, safinamide, added 1 hour before veratridine, reduces the neuron damage with an  $\text{IC}_{50}$  1.4  $\mu\text{M}$  (figure 6), supporting that the functional blockade of opening voltage-dependent  $\text{Na}^{+}$  and  $\text{Ca}^{2+}$  channels results in neuroprotection.




Figure 6. Effect of safinamide on veratridine-induced cell death in rat cortical neurons.

View larger version (73K):

[\[in this window\]](#)  
[\[in a new window\]](#)

**MPTP model in mice (therapeutic schedule).** Prevention of neuron death observed with a compound administered after MPTP suggests a neuroprotective mechanism independent of MAO-B inhibition. When given 4 hours after MPTP (radiochemical HPLC detection studies have shown that 4 hours after [ $^{14}\text{C}$ ]-methyl-MPTP administration to mice, the conversion of MPTP to  $\text{MPP}^{+}$  by MAO-B is complete), safinamide does not prevent the striatal DA decrease, which reflects the acute action of  $\text{MPP}^{+}$  taken up by the terminals, but significantly inhibits cell body degeneration in the substantia nigra pars compacta (figure 7). These results demonstrate that safinamide is endowed with neuroprotectant mechanisms in addition to MAO-B inhibition.





Figure 7. Neurorescuing effect of safinamide administered 4 hours after MPTP on nigral dopaminergic neurons in C57BL mice. \* $P < 0.05$  vs MPTP; \*\* $P < 0.01$  vs MPTP.

View larger version (53K):

[\[in this window\]](#)  
[\[in a new window\]](#)


**Kainic acid model in rats.** Seven days after injection, kainic acid, a rigid analogue of glutamate, induces neuronal hippocampal degeneration. Safinamide administered 15 minutes before kainic acid protects against hippocampal neuron loss, starting at 10 mg/kg showing neuroprotective properties (figure 8).



View larger version (42K):  
[\[in this window\]](#)  
[\[in a new window\]](#)


*Figure 8. Neuroprotective effect of safinamide on hippocampal neuronal cell loss induced by kainic acid in rats. \* $P < 0.05$  vs vehicle. Note the neuron loss in the vehicle-treated rats, while rats pretreated with safinamide show little evidence of damage, as shown by the abundance of normal healthy cells with clear cytoplasm.*

**Ischemia model in gerbils.** Bilateral carotid occlusion (BCO) in mongolian gerbils is an accepted model of transient ischemia resulting in hippocampal neuron loss. In a first series of experiments, safinamide (100 mg/kg IP) was administered 30 minutes before and after BCO. The neuron damage is almost completely prevented by safinamide (figure 9). To better define the time frame of the protective effect, in a second series of experiments safinamide was given at different times only after BCO. In this protocol, safinamide shows a relevant neurorescuing effect on hippocampal neurons when given 3 hours after ischemia (figure 10).



View larger version (20K):  
[\[in this window\]](#)  
[\[in a new window\]](#)

*Figure 9. Neuroprotective effect of safinamide on ischemia-induced hippocampal neuron death in gerbils. \*\* $P < 0.01$  vs sham.*



View larger version (40K):  
[\[in this window\]](#)  
[\[in a new window\]](#)

*Figure 10. Neurorescuing effect of safinamide on ischemia-induced hippocampal neuron death in gerbils. \* $P < 0.01$  vs sham.*

**Pharmacokinetic properties.** Preclinical pharmacokinetic studies were performed in mice, rats, and

monkeys after administration of safinamide given as a single IV or oral dose or as daily multiple oral doses. Safinamide has a high oral bioavailability (80–92%), is rapidly absorbed and, in plasma, after reaching the peak within 0.5–2 hours declines, with a terminal half-life of about 3, 7, and 13 hours in mice, rats, and monkeys, respectively. Brain levels of safinamide are always higher than the corresponding plasma concentrations, with a brain to plasma ratio of 16, 16, and 9 in mice, rats, and monkeys, respectively. At current pharmacologic doses, the brain levels of safinamide are expected to be in the high  $\mu\text{M}$  range.

Assuming the same brain:plasma ratio known for monkeys, plasma levels of 5–6  $\mu\text{M}$  that are seen in humans at steady state after 7 days of an oral dose of 150 mg should correspond to brain level of 40–50  $\mu\text{M}$ . Therefore, all pharmacodynamic properties of safinamide should be at play with clinically used doses and expected to concurrently exhibit their effects.

## ► Conclusions.

Safinamide, currently in phase III trials for the treatment of PD and in phase II trials for epilepsy, is a unique molecule with multiple mechanisms of action and with a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with voltage-dependent  $\text{Na}^+$  and  $\text{Ca}^{2+}$  channel blockade and glutamate release inhibition.

- ▲ Top.
- ▲ Abstract.
- ▲ Pharmacodynamic properties.
- Conclusions.
- ▼ Acknowledgment
- ▼ References

Safinamide has neuroprotective and neurorescuing effects in the mouse MPTP model, in the rat kainic acid model, and in the gerbil ischemia model, potentiates levodopa-mediated increase in DA levels in DA-depleted mice, and reverses the motor response complications of long-term L-dopa treatment in 6-OHDA-lesioned rats. Safinamide has an excellent bioavailability, linear kinetics, and a long half-life. It is very safe, well tolerated, and suitable for once-a-day administration.

All the pharmacodynamic properties are manifested at concentration that should be easily reached in the ongoing clinical trials. Therefore, safinamide might be used in PD to reduce levodopa dosage. Furthermore, it represents a valuable test to assess the clinical validity of experimental mechanisms that are expected to modify disease progression.

## ► Acknowledgment

The authors thank Ms Roberta Galbiati for excellent secretarial assistance.

- ▲ Top.
- ▲ Abstract.
- ▲ Pharmacodynamic properties.
- ▲ Conclusions.
- Acknowledgment
- ▼ References

Publication of this supplement was supported by a grant from Newron Pharmaceuticals.

Disclosure: C.C., R.M., M.C., L.F., L.C., and P.S. are employees of the sponsor and have an equity interest or ownership interest in the sponsor. S.M. is an employee of the sponsor. R.G.F. was an



employee of the sponsor until May 2005.

*Neurology* supplements are not peer-reviewed. Information contained in *Neurology* supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of *Neurology*.

## References

1. Hornykiewicz O. Biochemical aspects of Parkinson's disease. *Neurology* 1998;51(suppl 2):S2–S9.[[Abstract](#)]
2. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson's disease. *Neurology* 2002;58:179–185.[[Abstract/Free Full Text](#)]
3. Corti O, Brice A. Parkin,  $\alpha$ -synuclein and other molecular aspects of Parkinson's disease. *J Soc Biol* 2002;196:95–100.[[Medline](#)]
4. Warner TT, Shapira AH. Genetic and environmental factors in the cause of Parkinson's disease. *Ann Neurol* 2003;53(S3):S16–S23.[[Medline](#)]
5. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. *Neurology* 1998;50:S17–S25.[[Abstract](#)]
6. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. *Neurology* 2003;60:1234–1240.[[Abstract/Free Full Text](#)]
7. Stocchi F, Olanow CW, Hunot S, et al. Neuroprotection in Parkinson's disease: clinical trials. *Ann Neurol* 2003;53(S3):S87–S99.[[Medline](#)]
8. Jenner P. Oxidative stress in Parkinson's disease. *Ann Neurol* 2003;53(S3):S26–S38.[[Medline](#)]
9. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. *Ann Neurol* 2003;53(S3):S49–S58.[[Medline](#)]
10. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. *Ann Neurol* 2003;53(S3):S73–S84.[[Medline](#)]
11. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. *Ann Neurol* 1998;44(3 suppl 1):S89–S98.[[Medline](#)]
12. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. *J Neurochem* 1997;68:33–39.[[Medline](#)]
13. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. *J Neurochem* 1986;46:1359–1365.[[Medline](#)]
14. LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. *Neurology* 2004;63(7 suppl 2):S23–S31.[[Free Full Text](#)]
15. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. *N Engl J Med* 1989;321:1364–1371.[[Abstract](#)]
16. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. *Brain Res* 1994;662:69–74.[[Medline](#)]

[▲ Top.](#)  
[▲ Abstract.](#)  
[▲ Pharmacodynamic properties.](#)  
[▲ Conclusions.](#)  
[▲ Acknowledgment](#)  
[▲ References](#)

**This article has been cited by other articles:** (Search Google Scholar for Other Citing Articles)



F. Stocchi, L. Vacca, P. Grassini, M. F. De Pandis, G. Battaglia, C. Cattaneo, and R. G. Fariello

**Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition**

Neurology, October 10, 2006; 67(7\_suppl\_2): S24 - S29.

[Abstract] [Full Text]

*This Article*

- › [Abstract](#) FREE
- › [Figures Only](#)
- › [Correspondence:](#)  
[Submit a response](#)
- › [Alert me when this article is cited](#)
- › [Alert me when Correspondence are posted](#)
- › [Alert me if a correction is posted](#)
- › [Citation Map](#)

*Services*

- › [Email this article to a friend](#)
- › [Similar articles in this journal](#)
- › [Similar articles in PubMed](#)
- › [Alert me to new issues of the journal](#)
- › [Download to citation manager](#)

*Google Scholar*

- › [Articles by Caccia, C.](#)
- › [Articles by Fariello, R. G.](#)

*PubMed*

- › [PubMed Citation](#)
- › [Articles by Caccia, C.](#)
- › [Articles by Fariello, R. G.](#)

# Symptom relief in Parkinson disease by safinamide

## Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

F. Stocchi, MD, PhD; L. Vacca, MD, PhD; P. Grassini, MD; M.F. De Pandis, MD, PhD; G. Battaglia, MD; C. Cattaneo, PhD; and R.G. Fariello, MD

**Abstract**—In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4.2 points;  $P < 0.001$ ). In association with levodopa, the same doses of safinamide in another group of patients ( $N = 11$ ) induced a significant decrease in motor fluctuations (UPDRS part IV, 2.1 points;  $P < 0.001$ ), accompanied by a dose-proportional increase of the levodopa AUC, up to 77% from baseline. Because MAO-B was fully inhibited (95%) at all doses tested, we suggest that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine re-uptake. These hypotheses are under investigation and will pursue confirmation in controlled clinical trials.

NEUROLOGY 2006;67(Suppl 2):S24-S29

Safinamide is a benzylamino derivative with anticonvulsant,<sup>1</sup> antiparkinson,<sup>2</sup> and neuroprotectant<sup>3,4</sup> properties. Safinamide blocks Na and Ca channels in a use- and frequency-dependent manner with an  $EC_{50}$  at around 20–30  $\mu$ M; it also inhibits glutamate release ( $EC_{50}$  10  $\mu$ M).<sup>5</sup> In addition, safinamide is a potent reversible and highly specific MAO-B inhibitor,<sup>6</sup> providing complete platelet MAO-B inhibition in humans at serum levels  $\geq 0.5$   $\mu$ g/ml without affecting MAO-A at doses 20 times higher.<sup>7</sup> In a recent double-blind placebo-controlled study,<sup>8</sup> two doses of safinamide (mean and median doses of 40 and 70 mg/day) were administered for 3 months to moderately ill PD patients. The higher dose (calculated to be in the range that would block glutamate release and ion channels) provided significant improvement in all preset efficacy end points. The lower dose (calculated to provide complete MAO-B inhibition) resulted only in a trend toward efficacy. These results suggested that MAO-B inhibition was only one component of safinamide's therapeutic efficacy and that patients under treatment with a stable dose of one DA agonist responded better than treatment-free pa-

tients. This latter feature was postulated to be the result of combined D1 and D2 receptor stimulation. The commercially available agonists mostly stimulate D2 receptors, whereas safinamide should induce a significant elevation of endogenous DA, the natural ligand of both D1 and D2, resulting in a levodopa-like clinical effect.

A pilot study was therefore designed to seek further evidence that higher safinamide doses may cause greater symptomatic improvement and that MAO-B inhibition is only a small component in safinamide's symptomatic effect. In addition, the effects of escalating safinamide doses added to levodopa both on symptoms and on levodopa, DA, and DA metabolite serum levels were explored.

**Methods.** This was an open pilot single-center study. Safinamide was administered orally for 6 consecutive weeks to informed and consenting PD patients starting with the initial dose of 100 mg once a day and increasing to 150 and 200 mg by two 2-week steps, then entering a 2-year treatment at the high-

From the IRCCS San Raffaele Pisana, Rome Italy (F.S., P.G.), IRCCS NEUROMED Pozzilli IS Italy, San Raffaele Cassino FR Italy (L.V., G.B.), Newron Pharmaceuticals Bresso (Milano), Italy (C.C.), and Department of Neurology, T. Jefferson University, Philadelphia, Pennsylvania (R.G.F.). Publication of this supplement was supported by a grant from Newron Pharmaceuticals.

**Disclosure:** The sponsor has provided P.S. with an honorarium for his participation in this project (in excess of \$10,000) and honorarium during his career (in excess of \$10,000). G.B. has received grant support from the sponsor during his career. R.G.F. was an employee of the sponsor until May 2005. C.C., L.V., M.F.D.P., and P.G. report no conflicts of interest.

Address correspondence and reprint requests to Dr. Ruggero Fariello, Newron Pharmaceuticals spa, Via Ludovico Ariosto 21, 20091 Bresso (MI), Italy; e-mail: ruggero@fariello.com

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology.

est tolerated dose. The protocol was approved by the institution's Ethics Committee.

**Inclusion criteria.** Two groups of patients were studied. Group 1 consisted of white males and females  $\geq 30$  years of age who were affected by idiopathic PD, Hoehn and Yahr stages III-IV and were suffering from motor fluctuations while receiving a stable dosage of L-dopa (plus a decarboxylase inhibitor). Patients enrolled in group 2 were taking single DA agonist monotherapy for at least 4 weeks before the screening visit. All were willing to participate and were able to understand and sign the approved Informed Consent form.

**Exclusion criteria.** Women of childbearing potential, history of alcohol or drug abuse, presence of an ongoing pathologic process other than PD, history of glaucoma, allergic reaction to antiepileptic drugs, previous pharmacologic treatment that might have interfered with safinamide, presence of postural hypotension, or with liver enzyme at screening visit greater than twice the upper limits of normal were excluded. Consumption of foods high in tyramine content was forbidden.

On day 6 of the run-in period, eligible L-dopa-treated patients presented for baseline clinical evaluation (Unified Parkinson Disease Rating Scale, UPDRS; Clinical Global Impression, CGI) and blood sampling collection for measurement of platelet MAO-B activity and levodopa dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) levels, to be repeated at 60, 120, 180, and 240 minutes after levodopa intake. On day 7, all patients returned to the clinic for reassessment of UPDRS parts II, III, and IV and CGI part I, after which they received the first administration of the test drug and were given a 2-week supply of 50-mg capsules to be taken fasting in the morning, two of them in the first 2 weeks, and then three and four in the successive 2-week periods. Compliance was checked by sampling of safinamide blood levels 3 hours after drug intake at each return visit.

To collect preliminary data on extended tolerability and efficacy, at the end of the 12-week period patients entered a 2-year extension treatment, taking the maximal tolerated dose and being evaluated every 4 months.

**Criteria for evaluation.** *Efficacy.* Changes in clinical conditions were assessed by performing UPDRS part II, III, and IV dyskinesia scale and the CGI evaluation every second week and were compared to the baseline.

*Safety.* Safety was assessed by spontaneous reporting of adverse events (AEs) recorded by the patients and by performing hematologic and biochemical tests as well as vital signs, urinalysis, and ECG screening at baseline and every 2 weeks. Visual evoked potentials (VEPs) were performed at baseline and at study end.

*Evaluation of biomarkers.* MAO-B enzyme activity assay in platelet-rich plasma (PRP). The

MAO-B enzyme activity was assessed in PRP by a radioenzyme assay using [ $^{14}\text{C}$ ]-PEA as selective substrate.<sup>9</sup> The enzymatic activity was expressed as pMoles of substrate transformed/mg protein/hour.

*Plasma catecholamine levels.* The plasma catecholamine levels (DA, dihydroxyphenylacetic acid, homovanillic acid, and levodopa) were measured using HPLC coupled to an electrochemical detector with slight modification from a previously described method.<sup>10</sup>

*Statistical analysis.* The sample size of 22 evaluable subjects was calculated for detecting a linear trend among the three doses of safinamide in the changes from baseline of total score of UPDRS section III, with the following assumptions: pool standard deviation of 4.2; power of the F-test of 80%; type I error of 5%,  $\alpha = 0.05$ . The effect of safinamide on the parameters measured by a continuous or discrete scale was analyzed by repeated-measurement analysis of variance (ANOVA) in the Per-Protocol (PP) sample and by ANOVA handled by GLM procedure of SAS in the Intent-To-Treat (ITT) sample. To compare the effect among visits, the polynomial contrasts were adopted to study the linear and quadratic trend. Paired t-test was used to assess the significance of changes from baseline at each treatment visit.

In the presence of dichotomous or categorical variables, the effect on time (doses) of safinamide was analyzed by Friedman's test in the PP sample and by repeated-measurement logistic analysis, handled by the GENMOD procedure of SAS, in the ITT sample and in the safety population.

All comparisons among visits or between groups were two-sided and a P value of 0.05 or less was taken as statistically significant. No adjustment of significance level of multiple comparisons was made to preserve the overall 5% level because of the explorative and descriptive nature of the comparisons.

**Results. Patients disposition.** Twenty-five patients were screened and entered the study, one dropping out after the first test drug administration for unknown reasons. Eleven patients were under levodopa treatment and 14 under treatment with a DA agonist (6 pramipexol, 5 ropinirole, 3 cabergoline). In the former group, patients were older ( $65.9 \pm 10$  versus  $51.6 \pm 8$ ), had worse scoring on CGI I (10 moderately, one markedly ill, versus one borderline, 7 mildly, and 6 moderately ill) and UPDRS-IV ( $5.12 \pm 1.8$  versus  $1.2 \pm 1.2$ ). UPDRS-III was not different in the two groups averaging  $16.0 \pm 2.8$  and  $17.1 \pm 4.9$ . Twenty-four patients were at stage III of the Hoehn and Yahr scale and one in the levodopa group was at stage IV.

Ten levodopa (one withdrawn for a nonserious AE; see below) and 13 DA agonist patients completed the study. Two of these patients had their levodopa dose decreased by one-third.

Overall, safinamide was well tolerated at all tested doses (table). No serious AEs were reported.

Table Adverse events (AEs) during the study\*

AEs by body system and WHO preferred term	L-Dopa		DA agonist		Total	
	n	%	n	%	n	%
Patients exposed to treatments	11	100	14	100	25	100
Psychiatric	1	9.1	6	42.9	7	28.0
Confusion	1	9.1	2	14.3	3	12.0
Visual hallucination			3	21.4	3	12.0
Auditory hallucination			1	7.1	1	4.0
Agitation, nervousness			2	14.3	2	8.0
Insomnia			1	7.1	1	4.0
Libido decrease			1	7.1	1	4.0
Body as whole	2	18.2			2	8.0
Fever	2	18.2			2	8.0
Gastrointestinal			1	7.1	1	4.0
Gastrointestinal pain			1	7.1	1	4.0
Urinary system	1	9.1			1	4.0
Cystitis	1	9.1			1	4.0
Ocular system	1	9.1			1	4.0
Visual disturbances	1	9.1			1	4.0
Skin and appendages	1	9.1			1	4.0
Itchiness	1	9.1			1	4.0

\* The DA agonist group had a higher rate of psychiatric symptoms, as expected with these drugs. There was only one AE-related withdrawal, a patient experiencing itching and visual disturbances simultaneously. All AEs were transient and reverted promptly to normal.

All instrumental and laboratory assessments, including VEP, did not reveal abnormalities deemed to be of clinical relevance. One patient dropped out for AE (itching), which promptly resolved. Four episodes of hallucination occurred in association with DA agonists, an event often reported with this class of drugs.

**Biochemical markers.** The results of platelet MAO-B activity are shown in figure 1. The lowest dose of 100 g/day caused complete (97%) MAO-B inhibition at the first measurement in all patients. Enzyme activity was inhibited to the same degree throughout the study.

**Safinamide serum levels.** Serum levels of safinamide confirmed good compliance in all patients. Regression analysis showed a significant dose-concentration relationship and linearity to the dose. There were no significant differences between the levels in the levodopa and the DA agonist group (data not shown).

**Dopamine and metabolite serum levels.** Dopamine levels showed a moderate nonsignificant increase of about 30% compared to the baseline levels. The magnitude of this increment was the same independently of the safinamide dose (figure 2A). The dopamine metabolites DOPAC and HVA did not show statistical variation during safinamide treatment versus the pretreatment period (data not shown).

**Levodopa serum levels.** The addition of safinamide to levodopa produced a significant progressive augmentation of the levodopa serum AUC ranging from 56% at the dose of 100 mg/day to 88% with 200 mg (figure 2B).

**Efficacy.** In DA agonist-treated subjects, UPDRS Part II improved from a mean initial value of 6.1 to 5.1 at week 6. When safinamide was associated with






Figure 1. MAO-B activity in plasma PRP in 10 levodopa-treated patients at baseline and after adding incremental doses of safinamide: 100, 150, and 200 mg/day each dose for 2 weeks. From the lowest dose upward there is a <95% enzyme inhibition.



**Figure 2.** (A) Levels of serum DA measured at baseline and after addition of safinamide 100, 150 and 200 mg/day. Compared to baseline there is a dose-independent stable increment of about 30% that does not reach statistical significance. This effect is interpreted as the effect of peripheral MAO-B inhibition. (B) Area under the curve of serum levodopa levels is increased proportionally to the dose of safinamide added to the treatment, reaching 88% compared to baseline (no safinamide added).

levodopa it decreased from 6.1 to 4.2 at week 6. These results did not reach statistical significance.

A progressive decrease of UPDRS III score was seen in patients receiving a DA agonist (figure 3A).

From a mean baseline of 18.0 points ("on" phase) a decrease was seen to 15.9 after 2 weeks ( $P$  [t-test] = 0.02), then 14.6 at week 4 ( $P < 0.001$ ) and 13.8 at week 6 ( $P < 0.001$ ). Levodopa-treated patients did not show a statistically significant decrement but rather an improvement trend starting from 16.3 points, moving to 16.2, at 2 weeks, then 15.1 at 4 weeks ( $p = 0.056$ ), and 14.9 at 6 weeks ( $P = 0.054$ ).

On the contrary, UPDRS IV mirrored the results for part III. Whereas the improvement did not reach statistical significance in DA-agonist treated subjects, levodopa patients performed significantly bet-

ter after 100 mg (from mean score of 5.1 to 3.9;  $P = 0.008$ ) and even more so after 150 mg (score 3.0;  $P < 0.001$ ), an improvement that was maintained with 200 mg/day (2.9;  $P < 0.001$ ) (figure 3B).

**Discussion.** Safinamide serum levels were linear and dose proportional in association with both levodopa and DA agonists. In a previous study, linearity and lack of interference between safinamide and antiepileptic drugs was demonstrated at the same dose range.<sup>11</sup> This study therefore suggests lack of metabolic interference between safinamide on the one hand and levodopa and dopamine agonists on the other.


The administration of safinamide at doses equal to or greater than 100 mg/day was very well tolerated and caused a close to 100% inhibition of peripheral MAO-B from the lowest dose upward. In patients under stable treatment with a DA agonist, symptoms improved at each increment of the safinamide dose. This inhibition is likely to have determined the moderate increase of DA levels of about 30% over the baseline, which remained constant under all doses. Therefore, these results further support the hypothesis of symptom-relieving effects by safinamide far beyond MAO-B inhibition.

Assays for determination of levodopa, DA, and metabolite levels gave unexpected results because the levodopa AUC was progressively increased. Peripheral levodopa levels may be raised by inhibiting the main metabolizing enzymes dopadecarboxylase and catechol-O-methyl transferase (COMT). Dopa decarboxylase was already inhibited by the presence of benserazide or carbidopa in the levodopa formulations. With COMT inhibitors, variable increases have been reported,<sup>12-15</sup> ranging from 21% to 61%, with the greatest increase reported by Napolitano et al.<sup>15</sup> after 6-week treatment with tolcapone TID. Furthermore, the increase was in parallel with the increment of safinamide doses. The fact that MAO-B was fully inhibited at all doses therefore militates against an unlikely role of MAO inhibition in raising levodopa levels. Based on these results, safinamide was tested in separate studies as a potential COMT and L-dopa decarboxylase inhibitor and was found to be totally inactive. We hypothesize that the putative DA uptake inhibition deriving from safinamide itself, in addition to the one seen as a consequence of MAO-B inhibition, may contribute to this levodopa elevation. Experimental evidence suggests that increased peripheral levodopa signifies increased DA availability to the brain. In parallel with the increased peripheral levodopa, a significant reduction of dyskinesia was observed at the doses of 100 and 150 mg, without further improvement at 200 mg.

The efficacy data must be interpreted with caution, this being an open study. There is no satisfactory substitute for placebo. However, the following facts reinforce an optimistic interpretation of the results even under the present study limitations. (a) The data are remarkably similar to those obtained in

add-on to dopamine agonists  
mean changes from the baseline

Patients (n = 14) on a stable DA agonist  
dose  
of single dopamine agonist



# UPDRS IV




Figure 3. Mean changes of UPDRS scores (point variations on the ordinate) in patients after addition of increasing doses of safinamide. Significant (see text for statistics) and progressive decrease of UPDRS-III in addition to DA agonists (upper part, A) and of the UPDRS-IV, considered as a dyskinesia scale in patients treated with levodopa (lower part, B). In this latter group the maximal effect was seen after 150 mg and remained stable thereafter.

a placebo-controlled study.<sup>8</sup> (b) The observed effect increased with time, opposite to that expected with placebo, and was clearly different according to the associated therapy: diminishing motor fluctuations but not UPDRS-III in levodopa-treated patients and, conversely, improving motor performance in DA agonist-treated patients. (c) The biochemical data for the levodopa patients group demonstrated an improvement proportional to the increase of serum AUC, a well-known biochemical change capable of reducing motor fluctuations, particularly "off" time and also an objective dose-related finding unlikely explainable as a placebo effect.

Lastly, it can be questioned whether the incremental effect is due to a time effect rather than a dose effect. The reduction in UPDRS-III at the same time point (4 weeks of treatment) with three doses (two extrapolated from study 009 and one from the present study) from baseline was 1.5 points after 40 mg/day, 2.1 at 70 mg/day, and 3.4 after 150 mg/day, strongly suggesting at the same time a clear dose-

related improvement. Furthermore, in the present study a decrease of 4.2 UPDRS-III points was reached at week 6, whereas in study 009<sup>8</sup> the lower dose reached a 3-point decrease and the higher dose at 8 weeks. In the present study the highest dose obtained a higher degree of improvement at the same time point, and a similar degree of improvement was reached earlier than with the doses used in the 009 study. These data suggest a dose effect rather than a treatment duration-related effect.

In conclusion, this study demonstrated that safinamide causes a dose-dependent increase of peripheral levodopa comparable to the highest reported in the literature with tolcapone,<sup>16</sup> a potent COMT inhibitor. More experiments are necessary to fully explain the mechanism underlying this finding.

The results also support the hypothesis that MAO-B inhibition is a minor contributor to the symptomatic effect of safinamide in PD. Based on extrapolation from animal data in three species, including primates, glutamate release inhibition

should occur at the doses used, but its exact role is still under investigation. All the clinically available putative anti-glutamate drugs<sup>16-19</sup> have thus far failed to demonstrate motor improvement in clinical trials. However, whether or not these drugs clinically reach a cerebral concentration capable of exerting the anti-glutamate effect that they demonstrated in various experimental paradigms remains unclear. In primates with serum levels lower than those obtained in this study, safinamide is found in the brain at levels higher than the IC<sub>50</sub> for glutamate release inhibition.<sup>5</sup>

As an add-on to DA agonists, safinamide has confirmed clear improvement on the UPDRS-III. Because the improvement appeared earlier and the observation was terminated before the time at which maximal efficacy has been reported,<sup>8</sup> it seems logical to expect that the doses used in this study may offer greater benefit.

When safinamide was added to levodopa a lesser motor improvement was seen, probably reflecting the pre-existing optimal treatment regimen, but a significant reduction of "off" time without worsening of the dyskinesia scale occurred. Controlled clinical studies have been designed and are ongoing to test these expected improvements in a larger patient population.

## References

1. Fariello RG, McArthur R, Bonsignori A, et al. Preclinical evaluation of PNU151774E as a novel anticonvulsant. *J Pharmacol Exp Ther* 1996; 285:1151-1159.
2. Fariello RG, Caccia C. Safinamide. Effects on platelets MAO-B activity in healthy volunteers. *Proc 5th International Conference on Progress in Alzheimer's and Parkinson's disease* 2001. Abstract.
3. Mai R, Fariello R, Ulmar G, Varasi M, McArthur RA, Salvati P. PNU151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. *Eur J Pharmacol* 1998;359:27-32.
4. Vaghi F, Maj R, Rosa B, et al. Neuroprotective effect of PNU-151774E,

- a new anticonvulsant compound, in the model of Global Ischemia in gerbils. *Proc Society Neuroscience* 1997. Abstract.
5. Caccia C, Maj R, Calabresi M, et al. Safinamide from molecular targets to a new antiparkinson drug. *Neurology* 2006;67(suppl 2):S18-S23.
6. Strolin Benedetti MS, Murrari P, Colombo M, et al. The anticonvulsant FCB 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. *J Pharm Pharmacol* 1994;46:814-819.
7. Cattaneo C, Caccia C, Marro A, Maj R, Fariello RG. Pressure response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective reversible monoamine oxidase B inhibition. *Clin Neuropharmacol* 2003;26:203-213.
8. Stocchi F, Arnold G, Kwicinski H, et al. Improvement of motor function in early Parkinson disease by safinamide. *Neurology* 2004;63:746-748.
9. Robinson DS, Lovenberg W, Keiser H, Sjordama A. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. *Biochem Pharmacol* 1968;17:109-119.
10. Blandini F, Martignoni E, Pacchetti C, et al. Simultaneous determination of L-dopa and 3-O-methylidopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. *J Chromatogr [B] Biomed Sci Appl* 1997;700:278-282.
11. Perucca E, Quoff M, Thomas A, Cattaneo C, Fariello RG. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). *Epilepsy Res* 2004;51:12-14.
12. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. *Clin Neuropharmacol* 1996;19:222-238.
13. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. *Neurology* 1994;44:913-919.
14. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a six month double blind study in parkinsonian patients with levodopa related fluctuations. *J Neurol Neurosurg Psychiatry* 1996;60:36-40.
15. Napolitano A, Del Dotto P, Petrozzi L, et al. Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease. *Clin Neuropharmacol* 1999;22:24-29.
16. Parkinson Study Group. A randomized controlled trial of remacemide for motor fluctuations in Parkinson's disease. *Neurology* 2001;56:455-463.
17. Zipp F, Burklin F, Stecker K, Baas H, Fischer PA. Lamotrigine in Parkinson's disease—a double blind study. *J Neurol Transm Park Dis Dement Sect* 1995;10:199-206.
18. Janovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. *Parkinsonism Relat Disord* 2002;8:271-276.
19. Shintoh H, Vingerhoets FJ, Lee CS, et al. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, cross-over study. *Neurology* 1997;48:1282-1285.



- Levodopa is **self** regarded as the most effective agent for treating the motor symptoms of Parkinson's disease (PD)<sup>1</sup>
  - However, long-term use is associated with motor and non-motor side effects, with the most impact on quality of life.
- Patients with levodopa-induced motor fluctuations (for example, wearing off) usually require additional therapy (and therefore need the evidence to improve motor function) but are often not diagnosed. For this reason, there is a need for a new class of agent that extends to non-dopaminergic systems.
- Safinamide is an **alpha-synuclein** inhibitor in Phase III clinical development as an **add-on** therapy to dopamine agonists or levodopa. Safinamide has both dopamine and **non-dopamine** mechanisms of action, including non-synaptic inhibition of BDNF and **alpha-synuclein** inhibition, **calcium**-dependent **alpha-synuclein** channel transportation, and inhibition of glutamate release in **alpha-1**.

- To evaluate the effect of sulfonamide sex add-on to stable regimens on motor function and dyskinesias in patients with mid-to late-stage PD experiencing motor fluctuations

### Study design

- 24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study with four periodic reassessing, stabilization, treatment and tapering to the long-term extension study (Figure 1)

- Male to female patients aged 20 to 80 years with idiopathic F ( $>3$  years' duration), Hoehn and Yahr Stage I-IV and motor fluctuations ( $>1.5$  hours daily OFF time)
- Patients were excluded if they had well-unpredictable fluctuations or severe, disabling peak-dose or trough dyskinesia

- Sildenafil 50 mg/day, sildenafil 100 mg/day, or placebo as add-on therapy to levodopa
- The levodopa dose was to remain stable during the 24-week

- Patients or PD therapists other than MAO-B inhibitors were eligible for inclusion, but the dose had to remain stable during the treatment period, if possible
- If a patient's clinical condition warranted a change (increase/decrease) in the dose of levodopa or other PD therapies (i.e. a 25% or more clinically significant weight decrease or adverse events, respectively), all endpoint evaluations were carried out before the change was made.

\* The primary efficacy endpoint was the change (baseline to Week 24) in mean daily ON time (ON time without dyskinesia plus ON time with minor dyskinesia). This information was requested by subjects in a study diary.

Secondary endpoints include: the change (baseline to Week 24) in scores for the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (motor examination) and IV (complexity of therapy), and the Dyskinesia Rating Scale (DRS).

- Post hoc analyses on the UPDRG subscale scores were carried out to further evaluate the effect of saquinavir on motor function and dyskinesia (Table 1)

- Safety considerations include: treatment-emergent adverse events (TEAEs), laboratory data, and vital signs

[illegible]

**Statistical analysis**

- Least squares means changes (baseline to Week 24) between active treatment and placebo were compared using a mixed linear model (ON fixed and ANCOVA random effects) and Wilcoxon rank-sum test (NRS scores).

- In total, 669 patients were randomized to treatment (Table 2) and 504 patients (80%) completed the study.

[illegible]

Characteristic	Pre-2000 n=222	Subsequent 2001-2004 n=225	Subsequent 2005 onward n=225
Female, n (%)	126 (57.2)	127 (57.4)	126 (57.5)
Race, n (%)			
White	41 (18.4)	41 (18.5)	42 (18.7)
African	150 (68.1)	150 (68.2)	145 (65.6)
Age, years, mean (SD)	52.8 (8.4)	50.8 (8.3)	50.7 (8.1)
Current smoker, n (%)	51 (23.2)	51 (23.3)	51 (23.3)
Family size, mean (SD)	2.9 (1.2)	2.9 (1.2)	2.9 (1.2)
Child: 0-10 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 11-17 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 18-24 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 25-34 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 35-44 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 45-54 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 55-64 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 65-74 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 75-84 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 85-94 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 95-104 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 105-114 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 115-124 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 125-134 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 135-144 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 145-154 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 155-164 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 165-174 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 175-184 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 185-194 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 195-204 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 205-214 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 215-224 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 225-234 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 235-244 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 245-254 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 255-264 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 265-274 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 275-284 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 285-294 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 295-304 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 305-314 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 315-324 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 325-334 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 335-344 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 345-354 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 355-364 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 365-374 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 375-384 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 385-394 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 395-404 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 405-414 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 415-424 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 425-434 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 435-444 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 445-454 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 455-464 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 465-474 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 475-484 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 485-494 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 495-504 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 505-514 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 515-524 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 525-534 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 535-544 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 545-554 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 555-564 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 565-574 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 575-584 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 585-594 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 595-604 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 605-614 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 615-624 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 625-634 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 635-644 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 645-654 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 655-664 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 665-674 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 675-684 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 685-694 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 695-704 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 705-714 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 715-724 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 725-734 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 735-744 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 745-754 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 755-764 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 765-774 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 775-784 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 785-794 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 795-804 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 805-814 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 815-824 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 825-834 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 835-844 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 845-854 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 855-864 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 865-874 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 875-884 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 885-894 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 895-904 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 905-914 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 915-924 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 925-934 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 935-944 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 945-954 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 955-964 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 965-974 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 975-984 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 985-994 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 995-1004 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1005-1014 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1015-1024 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1025-1034 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1035-1044 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1045-1054 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1055-1064 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1065-1074 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1075-1084 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1085-1094 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1095-1104 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1105-1114 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1115-1124 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1125-1134 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1135-1144 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1145-1154 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1155-1164 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1165-1174 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1175-1184 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1185-1194 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1195-1204 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1205-1214 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1215-1224 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1225-1234 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1235-1244 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1245-1254 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1255-1264 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1265-1274 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1275-1284 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1285-1294 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1295-1304 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1305-1314 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1315-1324 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1325-1334 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1335-1344 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1345-1354 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1355-1364 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1365-1374 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1375-1384 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1385-1394 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1395-1404 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1405-1414 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1415-1424 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1425-1434 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1435-1444 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1445-1454 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1455-1464 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1465-1474 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1475-1484 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1485-1494 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1495-1504 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1505-1514 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1515-1524 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1525-1534 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1535-1544 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1545-1554 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1555-1564 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1565-1574 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1575-1584 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1585-1594 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1595-1604 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1605-1614 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1615-1624 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1625-1634 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1635-1644 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1645-1654 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1655-1664 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1665-1674 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1675-1684 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1685-1694 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1695-1704 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1705-1714 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1715-1724 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1725-1734 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1735-1744 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1745-1754 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1755-1764 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1765-1774 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1775-1784 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1785-1794 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1795-1804 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1805-1814 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1815-1824 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1825-1834 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1835-1844 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1845-1854 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1855-1864 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1865-1874 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1875-1884 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1885-1894 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1895-1904 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1905-1914 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1915-1924 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1925-1934 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1935-1944 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1945-1954 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1955-1964 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1965-1974 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1975-1984 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1985-1994 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 1995-2004 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2005-2014 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2015-2024 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2025-2034 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2035-2044 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2045-2054 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2055-2064 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2065-2074 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2075-2084 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2085-2094 years, n (%)	10 (4.5)	10 (4.5)	10 (4.5)
Child: 2095-2104 years,			


[illegible]

There were no significant differences between the asymptomatic groups for any demographic or disease-related characteristics (Table 2).

\* The myofascicle count was a nuclear double during the study, but there was a small increase in count (0.27%) in the placebo group; and small decreases in the sartanamide 50 and 100 mg/day groups (-1.05% and -2.16%,  $p=0.016$  for sartanamide 100 mg/day versus placebo).

The addition of rifampin to stable doses of levodopa resulted in significant increases in total daily ON time (without dyskinesia or with minor dyskinesia) in both naïve/naïve groups ( $+1.3$  h) versus placebo ( $0.83$  h) (Figure 2). There were no significant between-group differences for the change in ON time with troublesome dyskinesia ( $+0.2$  h for placebo,  $+0.3$  h for rifampine 60 mg/day, and  $+0.2$  h for rifampine 120 mg/day).


Figure 2. Mean change in ON time (ON without dyskinesia plus ON with severe dyskinesia) during the course of the study.



Using an ANCOVA analysis, all time points after baseline were statistically significant when compared with placebo, with the exception of salivary IL-6 levels at Week 18 and 20. CI, confidence interval; IL-6, interleukin-6; SE, standard error.

Both doses of salivarnade were associated with significant improvements in UPDRS Part II (motor examination) scores versus placebo (Figure 3). There were also significant improvements in the UPDRS Part III subscale scores for salivarnade 100 mg/day versus placebo (Table 3).

Figure 2. Least square means change in UPEdS Part 4 (motor examination) total score between baseline and Week 54.

[illegible]

© 2005 Thomson Reuters. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage and retrieval system, without prior written permission from Thomson Reuters. For more information, contact Thomson Reuters at 1-800-393-6343.

There were no statistically significant differences for either dose of asfidesine versus placebo for the change in UPDRS Part IV scores for dyskinesia and/or dystonia or for the CRS scores (Table 3).

Incidences of treatment-related TEAEs were 30% for sulfamamide 50 mg/day, 29% for sulfamamide 100 mg/day and 22.5% for placebo (p=0.209). The rate of discontinuation due to TEAEs was low (5–6%) and similar between treatment groups.

The most common TEAEs are shown in Table 4. Although cysteine was reported as a TEAE more frequently in the sulfonamide groups versus placebo, it was generally transient and not of concern in severity. Furthermore, there were no significant between-group differences for parent-reported ON line with: incontinence/dysphasia, or for the physician-rated LPRS Part IV scores (pulsate, no/less dysphasia) or QRS scores.

\* Changes in laboratory values and well signs were similar between treatment groups.

Copyright © 2004 John Wiley & Sons, Ltd.

Genes	Placenta (n=22) n (%)	Serum 30 weeks (n=22) n (%)	Serum 180 weeks (n=24) n (%)
Frequency of positive sequencing of each 1° BMD	1/27 (3.7%)	1/6 (16.7%)	5/6 (83.3%)
Chromosome			
13q32-q34	0/27 (0%)	0/6 (0%)	0/6 (0%)
15q21-q22	0/27 (0%)	0/6 (0%)	0/6 (0%)
17p11.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
18p11.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
21q22	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q11.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q13.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q31.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q36.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q37.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q38.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q39.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q40.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q41.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q42.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q43.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q44.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q45.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q46.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q47.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q48.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q49.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q50.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q51.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q52.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q53.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q54.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q55.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q56.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q57.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q58.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.7	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.8	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q59.9	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.1	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.2	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.3	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.4	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.5	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.6	0/27 (0%)	0/6 (0%)	0/6 (0%)
22q60.7			

- Based on patient diary data, add-on therapy with subacemide significantly improved ON time with non-troublesome dyskinesia in patients with levodopa-induced motor complications; it also significantly improved overall motor function in these patients

- Dyskinesia reported as a TEAE was more frequent in the rufinamide group than in placebo, but was generally transient and mild or moderate in severity. All other TEAEs were similar in incidence to placebo.

\* Sulfamonomethoxime was also well tolerated in this population of patients; incidences of TAEs leading to discontinuation and

changes in laboratory and vital-sign data were recorded.

- The effects of caffeine as an add-on therapy in patients with levodopa-induced motor complications are also being studied in the ongoing SETTLE study (see Poster 378)

1. LeWitt PA. Parkinsonism. *Textbook Neurology*. 15 (August 1). 521-534
2. Hunter RA. *Excerpta Medica* 2009; 62: 1-6
3. Ebrahimi-EB, Hunter RA. *Int Neuro* 2010; 60: 67-69
4. Pavesio L et al. *J Med Chem* 1995; 41: 579-590
5. Coscia C et al. *Neurology* 2008; 61: 826-832
6. Coscia C et al. *Pharmacokinetics Reson Drugs* 2007; 33 (August): 856

[illegible]

**Conclusion:** Case-control studies in genetically homogeneous populations are the most efficient paradigm for the association of genes in complex traits. The homogeneous population of Trondheim, Norway has allowed us to dissect the haplotype structure of the Tau gene and refine the functional variability associated with PD and PSP.

# P78

## The Nurr1 7048 G 7049 intronic insertion is not associated with Parkinson's disease

D.G. Healy, P. Sleimann, M.G. Sweeney, N. Khan, L.H. Eunson, N.W. Wood (London, UK)

**Objective:** To establish whether the Nurr1 gene which is critical for midbrain dopaminergic cell development and survival is a risk factor associated with PD.

**Background:** Nurr1 is an orphan nuclear receptor and functions as a transcriptional activator of tyrosine hydroxylase and the dopamine transporter gene. Knockout mice do not develop nigral dopaminergic neurones and heterozygous knockout mice have increased sensitivity to MPTP neurotoxicity. Mutations in exon 1 have been reported to segregate in a dominant manner with familial PD.

A recent study showed that patients with homozygosity for the 7048 G 7049 intronic insertion were 8.4 times more likely to develop PD than those who were homozygous for the wild type allele. They also speculated that this may have had a role in the expression of the gene.

**Methods:** Our study included 381 cases of PD consisting of 224 sporadic PD cases, 131 of whom were pathologically proven. 104 cases of young onset PD and 53 familial cases. We used 231 control samples of whom 160 did not have pathological evidence of PD. Genotyping for the 7048 G 7049 polymorphism was done using the restriction enzyme BsrRI and representative samples were confirmed using direct sequencing.

**Results:** We did not find any association that reached statistical significance between sporadic, YOPD, or fPD and control populations with either heterozygosity or homozygosity for the Nurr1 polymorphism. The results are displayed below (see Table).

**Conclusion:** We did not detect the association with Nurr1 as previously reported. There may be several reasons for this including population stratification, differences in the linkage between populations, patient numbers too small to detect modest factors and statistical artefact. Association studies are powerful way to identify disease susceptibility loci in complex disorders like PD. Further studies using larger numbers, linkage disequilibrium, and genomically matched controls are needed to establish the role of Nurr1 in PD.

	Controls, n (%)	Total PD, n (%)	Sporadic PD, n (%)	YO PD, n (%)	fPD, n (%)
Wild type	144 (62.3%)	223 (58.5%)	133 (59.4%)	62 (59.6%)	28 (52.8%)
Heterozygous	77 (33.3%)	143 (37.5%)	82 (36.6%)	38 (36.5%)	23 (43.4%)
Homozygous	10 (4.3%)	15 (3.9%)	9 (4%)	4 (3.8%)	2 (3.8%)

# P79

## Two different phenotypes of the same Parkin mutation in a large pedigree

N. Hattori, R. Inzelberg, P. Nispeanu, S. Blumen, R.L. Carasso, Y. Mizuno (Tokyo, Japan; Hadana, Israel)

**Objective:** To describe two different phenotypes of a parkin mutation observed in a large pedigree.

**Background:** Autosomal recessive juvenile parkinsonism (AR-JP) has been related to mutations in the parkin gene. Genotype-phenotype correlation is not yet determined.

**Methods:** Members of a large Arabic Muslim Israeli family have been followed for 15 years. Genomic DNA was extracted from blood leukocytes and examined using RFLPs and direct sequencing of all 12 exons of the parkin gene.

**Results:** The consanguinity of the affected branches of the family was established back to the seventh ancestral generation. In the first branch, a deletion of one A at position 202 in exon 2 of parkin gene was found. In this branch, four brothers (out of 10 siblings) were affected. Ages of onset were 35, 33, 37, 30 years and the disease duration 27, 22, 9 and 14 years. The onset and subsequent progression of parkinsonian symptomatology were similar for all four patients. Hand tremor was the first symptom; later bradykinesia and rigidity were observed. Additionally, all presented postural hand tremor. A maternal aunt who suffered only of postural tremor (onset 60 years) was found heterozygous for the same mutation. The second branch of the family (2 first-degree cousins affected) also carried an A deletion at position 202 in exon 2. The clinical picture was different and dominated by axial dystonia. The age of onset of the female patient was 23 years (duration of disease 40 years). The initial symptom was rest tremor in the upper limbs and difficulty in walking. Few years later, campocoria occurred which progressed gradually up to the development of permanent 90 degrees forward trunk flexion. The male patient's disease onset was at the age of 19 years (duration of disease 17 years) with tremor in upper and lower limbs, followed by rigidity and bradykinesia. He later developed axial dystonia expressed by scoliosis. Levodopa response was excellent for all patients. The total daily dose remained low (<500 mg) for up to 30 years. The axial symptoms of the second branch patients were levodopa responsive.

**Conclusions:** A parkin mutation was expressed by different phenotypes in a large pedigree. Axial dystonia may represent a major symptom in these patients. Postural tremor might be the expression of heterozygous mutations in parkin gene suggesting that gene dosage might influence the age at onset and phenotype of AR-JP.

# P80

## A 2-year, multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression

O. Rascol, W. Olanow, D. Brooks, G. Koch, P. Truffinet, R. Bejjani (Toulouse, France; New York, NY, USA; London, UK; Chapel Hill, NC, USA; Paris, France)

**Objective:** To assess if riluzole can slow the progression of Parkinson's disease (PD) in patients with early disease.

**Background:** Riluzole, a blocker of glutamatergic neurotransmission and sodium channels, has been shown to extend survival and/or time to tracheostomy in patients with amyotrophic lateral sclerosis. It also reduces 6-OH-DA and MPTP toxicity in various in vivo models of parkinsonism in rodents and monkeys.

**Methods:** This was a 2-year placebo-controlled, double-blind parallel study assessing the capacity of 2 doses of riluzole (50 mg b.i.d. or 100 mg b.i.d.) over 2 years to delay the progression of signs and symptoms of PD as determined by the ability of the drug to delay the initiation of levodopa or a dopamine (DA) agonists (primary endpoint) in untreated patients with early PD. Secondary endpoints were worsening of clinical symptoms assessed using the UPDRS after a 2-month wash-out at the end of the study, and functional integrity of striatal dopamine nerve terminals as measured with <sup>18</sup>F-Dopa PET scanning. Safety data were monitored throughout the study. Log-rank test in ITT population was used to compare time to levodopa or DA agonist between combined-riluzole and placebo groups (primary analysis). An interim analysis was planned after one third of the patients had reach 2 years of follow-up to propose early termination if there was not a reasonable possibility of success if the study were continued (futility analysis).

**Results:** 1084 PD patients were randomized (62.6 yr, 61% males, 17 months of disease duration). At interim analysis the predefined futility criteria were met. Then, the study was terminated prematurely, due to lack of efficacy. At the time of final analysis, 711/1084 patients had started levodopa or DA agonist. The probability of starting levodopa or DA agonist during the first 18 months was 0.69 on placebo and 0.71 on riluzole (Hazard Ratio 1.07, 95% CI 0.91, 1.26, P 0.41). There was no difference on secondary endpoints. AES were similar to that observed in previous studies and were more frequent on riluzole than on placebo.

**Conclusion:** Riluzole did not show superiority over placebo on PD progression.

# Effect of safinamide in depressive symptoms in patients with mid-late stage Parkinson's disease

Rupam Borghain,<sup>1</sup> Neeta A. Mehta,<sup>1</sup> Ovidiu A. Bajanaru,<sup>2</sup> Rocco Quatrone,<sup>3</sup> Valentina Lucini,<sup>4</sup> Ravi Anand,<sup>5</sup> for the Study 016 Investigators

<sup>1</sup>Neeta's Institute of Medical Sciences, Hyderabad, India; <sup>2</sup>Dr. Neeta Mehta Clinic, San Francisco, Mumbai, India; <sup>3</sup>University Emergency Hospital Bucharest, Romania; <sup>4</sup>University Hospital, Ferrara, Italy; <sup>5</sup>Neuron Pharmaceuticals, San Diego, Italy; <sup>6</sup>APC, AG, St. Moritz, Switzerland

324

## INTRODUCTION

- Depression is common in Parkinson's disease (PD). An estimated 35% of patients have had a significant depressive disorder, and 17% have major depressive disorder. Depression is associated with poor quality of life. It may lead to a negative impact on patients' ability to function and maintain caregiver burden. PD therapy should therefore be focused on improving global motor and depressive symptoms.
- The purpose of this study was to evaluate the efficacy of PD therapy on depressive symptoms in patients with mid-late stage PD and non-motor symptoms.
- Safinamide is an amphetamine-like dopamine-releasing agent in PD that has both dopaminergic and non-dopaminergic mechanisms of action.

## OBJECTIVE


The efficacy and safety of safinamide as add-on therapy to stable levodopa were assessed in a Phase II trial in patients with mid-late stage PD and motor fluctuations. Here, we report data on the effect of safinamide on depressive symptoms in study participants.

## METHODS

### Study design

24-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study with two groups: safinamide (100 mg/day) and placebo, and open-label for the long-term extension study (Figure 1).

### Figure 1. Study design



## Patients

- Male or female patients aged 50 to 65 years with idiopathic PD (>3 years duration) and Hoehn and Yahr Stage 3-4.
- Patients with motor fluctuations (>1 hours daily OFF times). Patients were included if they had stable, reproducible fluctuations of levodopa, without peak-dose or l-dopa dyskinesias.
- Patients with depression, defined as a GRD-HAMD total score  $\geq 17$ , were also included.

## Treatments

- Once-daily single dose of safinamide 50 mg/day, safinamide 100 mg/day, or placebo as add-on therapy to levodopa.
- The levodopa dose was to remain stable during the 24-week treatment period, if possible.
- Patients on PD therapies other than monotherapy with levodopa were eligible for inclusion, but the dose had to remain stable during the treatment period, if possible.
- If a patient's clinical condition warranted a change (increase or decrease) in the dose of levodopa or other PD therapies (e.g. in the event of clinically significant motor deterioration or adverse events, respectively), all protocol violations were noted but did not result in exclusion from the study.

## Assessments

- The primary efficacy endpoint was the change in mean daily ON time (ON time without dyskinetic dyskinesia) use with stable dyskinesia response in patients treated with safinamide or placebo from baseline to the end of the GRD-HAMD total score and the Parkinson's-related wellbeing subscale of the PD Questionnaire (PD-Q).
- The following post hoc analyses were carried out:
  - GRD-HAMD scores.
  - Change in GRD-HAMD total score (baseline to baseline scores < 19 and  $\geq 19$ ) and subscale scores.
  - Safety assessments in total population, treatment subgroups (TEASs), laboratory data, and vital signs.

## Statistical analysis

- Least squares (LS) means change (baseline to Week 24) between active treatment groups were compared using a mixed-effects model (ANCOVA) (other efficacy endpoints).

## RESULTS

- In total, 885 patients were randomized to treatment (Table 1) and 884 patients completed the study.
- There were no significant differences between the treatment groups for any demographic or disease-related characteristics (Table 1).

Characteristic	Placebo (n=222)	Safinamide 50 mg/day (n=222)	Safinamide 100 mg/day (n=222)
Gender, n (%)			
Male	182 (82.0)	182 (82.0)	182 (82.0)
Female	40 (18.0)	40 (18.0)	40 (18.0)
Age, mean (SD)	58.0 (7.0)	58.0 (7.0)	58.0 (7.0)
Age range, years	45-75	45-75	45-75
Age $\geq 65$ , n (%)	100 (45.0)	100 (45.0)	100 (45.0)
Age $< 65$ , n (%)	122 (55.0)	122 (55.0)	122 (55.0)
Mean (SD) weight (kg)	75.0 (15.0)	75.0 (15.0)	75.0 (15.0)
Mean (SD) weight (kg)	75.0 (15.0)	75.0 (15.0)	75.0 (15.0)
Mean (SD) weight (kg)	75.0 (15.0)	75.0 (15.0)	75.0 (15.0)

Characteristic	Placebo (n=222)	Safinamide 50 mg/day (n=222)	Safinamide 100 mg/day (n=222)
GRD-HAMD total score, mean (SD)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD subscale scores, mean (SD)			
GRD-HAMD-1 (motor)	10.0 (3.0)	10.0 (3.0)	10.0 (3.0)
GRD-HAMD-2 (non-motor)	9.0 (4.0)	9.0 (4.0)	9.0 (4.0)
GRD-HAMD-3 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-4 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-5 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-6 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-7 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-8 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-9 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-10 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-11 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-12 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-13 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-14 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-15 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-16 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-17 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-18 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-19 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-20 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-21 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-22 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-23 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-24 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-25 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-26 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-27 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-28 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-29 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-30 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-31 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-32 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-33 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-34 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-35 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-36 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-37 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-38 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-39 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-40 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-41 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-42 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-43 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-44 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-45 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-46 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-47 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-48 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-49 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-50 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-51 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-52 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-53 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-54 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-55 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-56 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-57 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-58 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-59 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-60 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-61 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-62 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-63 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-64 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-65 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-66 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-67 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-68 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-69 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-70 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-71 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-72 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-73 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-74 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-75 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-76 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-77 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-78 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-79 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-80 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-81 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-82 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-83 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-84 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-85 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-86 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-87 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-88 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-89 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-90 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-91 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-92 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-93 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-94 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-95 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-96 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-97 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-98 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-99 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-100 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)

GRD-HAMD: GRD-HAMD Rating Scale for Depression-17 items; PD: Parkinson's disease; SD: standard deviation.

## Efficacy

- The addition of safinamide to stable doses of levodopa resulted in significant increases in total daily ON time without dyskinesias in both safinamide groups versus placebo (Table 2).

Characteristic	Placebo (n=222)	Safinamide 50 mg/day (n=222)	Safinamide 100 mg/day (n=222)
GRD-HAMD total score, mean (SD)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD subscale scores, mean (SD)			
GRD-HAMD-1 (motor)	10.0 (3.0)	10.0 (3.0)	10.0 (3.0)
GRD-HAMD-2 (non-motor)	9.0 (4.0)	9.0 (4.0)	9.0 (4.0)
GRD-HAMD-3 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-4 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-5 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-6 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-7 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-8 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-9 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-10 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-11 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-12 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-13 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-14 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-15 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-16 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-17 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-18 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-19 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-20 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-21 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-22 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-23 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-24 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-25 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-26 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-27 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-28 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-29 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-30 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-31 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-32 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-33 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-34 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-35 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-36 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-37 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-38 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-39 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-40 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-41 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-42 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-43 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-44 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-45 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-46 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-47 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-48 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-49 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-50 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-51 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-52 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-53 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-54 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (5.0)
GRD-HAMD-55 (total)	19.0 (5.0)	19.0 (5.0)	19.0 (